Lapam Capital

Lapam Capital, headquartered in Beijing, is a leading biopharmaceutical venture capital firm in China. Currently, Lapam Capital manages five RMB funds and one USD fund, with a total scale exceeding 10 billion RMB. It is the only biopharmaceutical investment institution to have received funding support from both of China's top two RMB LP funds—the National Social Security Fund and the National Small and Medium Enterprise Development Fund. Lapam Capital focuses on investments in innovative drugs and innovative medical devices, primarily targeting startups and early to mid-stage companies. The firm has invested in over 60 innovative drug companies and more than 10 innovative medical device companies, including prominent projects such as Betta Pharmaceuticals (SZ.300558), RemeGen (SH.688331), Clover Biopharmaceuticals (HK.02197), Asia Pioneer Pharmaceutical (SH.688176), Stemirna Therapeutics, Bio-Ray Biotech, ImmuneOnco Biopharmaceuticals, Huahao Zhongtian, and Aiborn Medical Technology (SH.688050). Several partners on Lapam Capital’s management team possess over 20 years of international and domestic biopharmaceutical industry R&D and management experience, enabling them to provide comprehensive value-added services to portfolio companies.